信達生物(01801.HK)治療細胞癌新藥研究達其主要研究終點
信達生物(01801.HK)公布,與禮來製藥共同開發的創新PD-1抑制劑達伯舒(信迪利單抗注射液)的一項在中國開展的II期ORIENT-2研究-達伯舒用於二線治療晚期或轉移性食管鱗狀細胞癌患者達到總生存期主要研究終點。
該研究評估了達伯舒單藥療法相對於化療(紫杉醇或伊立替康)用於二線治療晚期或轉移性ESCC,數據證明顯著延長了總生存期,安全性特徵與既往報道的達伯舒研究結果一致,未發現新的安全性信號。詳細的研究結果將在今年ASCO會議上以壁報討論的形式予以發佈。(sw/W)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.